Associations - gedatolisib (PF-05212384)

HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	PF-05212384 Sensitive: B - Late Trials PF-05212384 Sensitive : B	PF-05212384 Sensitive: B - Late Trials PF-05212384 Sensitive : B
FGF19 amplification + ER positive	HER2 Negative Breast Cancer	FGF19 amplification + ER positive	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
EGFR mutation + ER positive	HER2 Negative Breast Cancer	EGFR mutation + ER positive	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
FGF3 amplification + ER positive	HER2 Negative Breast Cancer	FGF3 amplification + ER positive	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
ER mutation	HER2 Negative Breast Cancer	ER mutation	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
FGF4 amplification + ER positive	HER2 Negative Breast Cancer	FGF4 amplification + ER positive	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
PIK3CA E542Q	HER2 Positive Breast Cancer	PIK3CA E542Q	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3
PIK3CA amplification	HER2 Positive Breast Cancer	PIK3CA amplification	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3
PIK3CA N345K	HER2 Positive Breast Cancer	PIK3CA N345K	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3
PIK3CA E453K	HER2 Positive Breast Cancer	PIK3CA E453K	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3
PIK3CA H1047R	HER2 Positive Breast Cancer	PIK3CA H1047R	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3
PIK3CA E542K	HER2 Positive Breast Cancer	PIK3CA E542K	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3
PIK3CA H1047L	HER2 Positive Breast Cancer	PIK3CA H1047L	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3
ER Y537S	HER2 Negative Breast Cancer	ER Y537S	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
BRCA2 mutation	HER2 Negative Breast Cancer	BRCA2 mutation	HER2 Negative Breast Cancer	talazoparib + PF-05212384 Sensitive: C3 – Early Trials talazoparib + PF-05212384 Sensitive : C3	talazoparib + PF-05212384 Sensitive: C3 – Early Trials talazoparib + PF-05212384 Sensitive : C3
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	talazoparib + PF-05212384 Sensitive: C3 – Early Trials talazoparib + PF-05212384 Sensitive : C3	talazoparib + PF-05212384 Sensitive: C3 – Early Trials talazoparib + PF-05212384 Sensitive : C3
STRN-ALK rearrangement	Mesothelioma	STRN-ALK rearrangement	Mesothelioma	ceritinib + PF-05212384 Sensitive: D – Preclinical ceritinib + PF-05212384 Sensitive : D	ceritinib + PF-05212384 Sensitive: D – Preclinical ceritinib + PF-05212384 Sensitive : D
PIK3CA H1047R	Colon Cancer	PIK3CA H1047R	Colon Cancer	PF-05212384 Sensitive: D – Preclinical PF-05212384 Sensitive : D	PF-05212384 Sensitive: D – Preclinical PF-05212384 Sensitive : D
KRAS mutation	Colon Cancer	KRAS mutation	Colon Cancer	PF-05212384 Sensitive: D – Preclinical PF-05212384 Sensitive : D	PF-05212384 Sensitive: D – Preclinical PF-05212384 Sensitive : D
PIK3CA K111N	HER2 Positive Breast Cancer	PIK3CA K111N	HER2 Positive Breast Cancer	PF-05212384 Sensitive: D – Preclinical PF-05212384 Sensitive : D	PF-05212384 Sensitive: D – Preclinical PF-05212384 Sensitive : D
ABCB1 overexpression	Colorectal Cancer	ABCB1 overexpression	Colorectal Cancer	PF-05212384 Resistant: D – Preclinical PF-05212384 Resistant : D	PF-05212384 Resistant: D – Preclinical PF-05212384 Resistant : D
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	neratinib + PF-05212384 Sensitive: D – Preclinical neratinib + PF-05212384 Sensitive : D	neratinib + PF-05212384 Sensitive: D – Preclinical neratinib + PF-05212384 Sensitive : D
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	neratinib + PF-05212384 Sensitive: D – Preclinical neratinib + PF-05212384 Sensitive : D	neratinib + PF-05212384 Sensitive: D – Preclinical neratinib + PF-05212384 Sensitive : D
KRAS mutation	Colon Cancer	KRAS mutation	Colon Cancer	PF-05212384 + mirdametinib Sensitive: D – Preclinical PF-05212384 + mirdametinib Sensitive : D	PF-05212384 + mirdametinib Sensitive: D – Preclinical PF-05212384 + mirdametinib Sensitive : D
PIK3CA mutation	Colon Cancer	PIK3CA mutation	Colon Cancer	PF-05212384 + mirdametinib Sensitive: D – Preclinical PF-05212384 + mirdametinib Sensitive : D	PF-05212384 + mirdametinib Sensitive: D – Preclinical PF-05212384 + mirdametinib Sensitive : D
KRAS mutation	Colon Cancer	KRAS mutation	Colon Cancer	PF-05212384 Sensitive: D – Preclinical PF-05212384 Sensitive : D	PF-05212384 Sensitive: D – Preclinical PF-05212384 Sensitive : D
PIK3CA H1047R	Squamous Cell Carcinoma of Head and Neck	PIK3CA H1047R	Squamous Cell Carcinoma of Head and Neck	PF-05212384 Sensitive: D – Preclinical PF-05212384 Sensitive : D	PF-05212384 Sensitive: D – Preclinical PF-05212384 Sensitive : D
HRAS Q61L	Squamous Cell Carcinoma of Head and Neck	HRAS Q61L	Squamous Cell Carcinoma of Head and Neck	PF-05212384 Sensitive: D – Preclinical PF-05212384 Sensitive : D	PF-05212384 Sensitive: D – Preclinical PF-05212384 Sensitive : D
ABCG2 overexpression	Colorectal Cancer	ABCG2 overexpression	Colorectal Cancer	PF-05212384 Resistant: D – Preclinical PF-05212384 Resistant : D	PF-05212384 Resistant: D – Preclinical PF-05212384 Resistant : D

gedatolisib (PF-05212384)

Associations
(31)

Associations
(31)

gedatolisib (PF-05212384)

Associations(31)

Associations(31)

Associations
(31)

Associations
(31)